Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty patients with stage III and IV non-Hodgkin's lymphoma were treated by total-body irradiation (TBI). Eleven patients had previously received local radiotherapy or chemotherapy. Toxicity was confined to haematological depression. Complete remission of disease was achieved in 14 patients. Non-leukaemic patients who had received no previous treatment reacted best to TBI (ten complete remissions in 13 patients). We consider TBI a helpful treatment in non-leukaemic patients with advanced lymphosarcoma.
 ...
PMID:Total-body irradiation in advanced lymphosarcoma. 11 51

Cytophotometric DNA determinations on 26 cases of non-Hodgkin's lymphoma yielded the following findings: 1. Follicular centrocytic/centroblastic lymphomas (M. Brill-Symmers) and diffuse centrocytic lymphomas (lymphocytic lymphosarcoma) have a diploid DNA stem line. Diploid DNA values are observed in benign tumors, so that the assignment of these lymphomas to the group of "low grade malignancies" appears justified. 2. Lymphoblastic sarcomas show an aneuploid DNA stem line, as do 96% of all malignant tumors. 3. Lymphoid cells, plasma cells, and immunoblasts seen in immunocytomas are aneuploid. Thus these lymphomas must belong to the group of "high-grade malignant lymphomas" as regards their DNA distribution. 4. Immunoblastic sarcomas have aneuploid DNA stem lines (1 case tetraploid), in which both the lymphoid cells and the plasma cells from those immunoblastic sarcomas arising from immunocytomas show atypical DNTA distribution patterns. 5. In two cases of angioimmunoblastic lymphadenopathy, the lymphoid cells, plasma cells, and immunoblasts are aneuploid. They are thus regarded as "high grade malignancy" lymphomas. The results are discussed with respect to clinical course and prognosis. Measurements on a larger series of cases and correlation to clinical data are needed to support these results. Ultrafast DNA measurements made by flow-through cytophotometry can perhaps be helpful in the future for making the decision between a "low" or "high" grade malignant lymphoma.
 ...
PMID:DNA in non Hodgkin-lymphoma--a cytophotometric study. 33 46

Monocytopoietic proliferation activity was investigated in patients with untreated Hodgkin's disease, Hodgkin's disease in long-term complete remission, and untreated non-Hodgkin's lymphoma of the lymphosarcoma and reticulosarcoma type. Untreated Hodgkin's disease was found to be associated with a rise in medullary monocyte production which returned to normal during long-term complete remissions. In contrast, monocyte production was increased in only 5 out of 14 patients with lymphosarcoma and reticulum cell sarcoma, normal in 3, and reduced in 6. In neither of these lymphomas was any relation between monocyte production and stage or histology of the disease detectable.
 ...
PMID:Monocyte production in Hodgkin's disease and non-Hodgkin's lymphoma. 35 66

One hundred ninety patients who had advanced active Hodgkin's disease, lymphosarcoma, or reticulum cell sarcoma were treated with a combination of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) given in a cyclical fashion every month. Complete remission was produced in 91 of 138 (66%) patients with Hodgkin's disease and in 39 of 52 (75%) patients with non-Hodgkin's lymphoma (lymphosarcoma and reticulum cell sarcoma). The response rate was higher in patients who completed six cycles of therapy compared to those who completed only three to five cycles: 77% vs. 45%, respectively, in Hodgkin's disease, and 85% vs. 46%, respectively, in non-Hodgkin's lymphoma. The median duration of remission was longer for Hodgkin's disease patients who completed six cycles (30 months vs. 10 months). The median duration of complete remission of non-Hodgkin's lymphoma was 14 months. The response to treatment correlated positively with survival. The median survival time start of COPP treatment for patients with Hodgkin's disease was 7 months for nonresponders, 14 months for those who attained partial remission, and more than 48 months for those who attained complete remission. For patients with non-Hodgkin's lymphoma, the median survival time from start of COPP treatment was 24 months for nonresponders and those who had partial remission, and more than 32 months for those who attained complete remission. Of complete remission responders with Hodgkin's disease, 70% are still alive 84 months after diagnosis, and 63% of the patients witn non-Hodgkin's lymphoma are still alive 48 months after diagnosis.
 ...
PMID:Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. 110 Feb 20

At the department, 138 children with non-Hodgkin's lymphoma of the abdominal cavity and small pelvis were examined. Resulting from the combined and complex treatment, in stage II of the disease, the complete remission was noted in 9 patients; in stage III, the partial remission--in 14, complete remission--39; in stage IV--in 17 and 9, respectively. Sixteen (11.6%) patients died. In non-organic lymphosarcoma spread, the intensive polychemotherapy, with subsequent irradiation of the abdominal cavity at the total dosage of 20 Gr and all the revealed foci of lesion--up to 35--40 Gr is effective. In involvement of the alimentary canal, the extended resection of the affected area with administration after the operation of polychemotherapy and irradiation of the zones of metastatic spreading is indicated.
 ...
PMID:[Non-Hodgkin's lymphoma of the abdominal cavity and small pelvis in children]. 239 47

Results of second line chemotherapy schedules to treat refractory lymphoma have usually been poor. In this study we have treated 21 patients with advanced non-Hodgkin's lymphoma, usually heavily pretreated, with VINAP regimen. This original four drug chemotherapy combination included: Vindesine, 2 mg/m2 iv on days 1 and 2; CCNU, 40 mg/m2 oral on days 3 and 4; Cytosine arabinoside, 2.4 g/m2 iv on day 3 to 6 and methyl-Prednisolone, 80 mg/m2 on days 1 to 6. Sixteen patients (76%) showed response, including 5 (23%) who achieved a complete remission (CR). Eight patients achieved a partial remission (PR), and two patients obtained an objective response. Although the responses to VINAP regimen were dramatic and rapid in onset, usually they were of short duration except in cases of lymphosarcoma cell leukaemia. The median duration of response for patients with CR was 42 weeks and for PR 11 weeks. Toxicity was acceptable, including predictable myelosuppression, frequent mucositis and occasional polyneuritis. Neither central nervous problems nor conjunctivitis or dermatitis had been seen.
 ...
PMID:[Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas]. 275 50

Bovine leukemia virus (BLV) is the causative agent of enzootic bovine lymphosarcoma. Much speculation continues to be directed at the role of BLV in human leukemia. To test this hypothesis rigorously, a case-control study of childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma was conducted between December 1983 and February 1986. Cases (less than or equal to 16 years at diagnosis) derived from patients diagnosed at the primary institutions and affiliated hospitals were matched (age, sex, and race) with regional population controls. DNA samples from bone marrow or peripheral blood from 157 cases (131 acute lymphoblastic leukemia, 26 non-Hodgkin's lymphoma) and peripheral blood from 136 controls were analyzed by Southern blot technique, under highly stringent conditions, using cloned BLV DNA as a probe. None of the 157 case or 136 control DNA samples hybridized with the probe. The high statistical power and specificity of this study provide the best evidence to date that genomic integration of BLV is not a factor in childhood acute lymphoblastic leukemia/non-Hodgkin's lymphoma.
 ...
PMID:No involvement of bovine leukemia virus in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. 283 51

Several studies have suggested that forestry workers are at increased risk for certain types of cancer including soft-tissue sarcoma (STS) and non-Hodgkin's lymphoma (NHL). We now report a series of national case-control studies based on the New Zealand Cancer Registry (NZCR). These involved 19,904 male patients with cancer for the period 1980-1984 who were aged 20 years or more at the time of registration. For each cancer site, the registrations for the remaining sites formed the control group. Current or most recent occupational titles were coded. There was an increased risk for STS (OR = 3.24) in forestry workers which was confined to men under 60 years of age at registration. An elevation in risk for NHL (OR = 1.84) was due to an increase in risk for lymphosarcoma and reticulosarcoma (ICD 200) (OR = 3.18). Acute myeloid leukemia was also associated with forestry work, although the estimate of risk was imprecise (OR = 2.24). Among other cancer sites, an increase in risk of neoplasia of the upper gastro-intestinal tract (ICD 150, 151, 152) was demonstrated. Odds ratios were elevated for cancer of the esophagus (OR = 1.77), stomach (OR = 2.22), small intestine (OR = 5.22), gall-bladder (OR = 4.13) and pancreas (OR = 1.79), as well as for nasopharyngeal cancer (OR = 5.56). These increases in cancer risk were not present in sawmill workers in New Zealand during the same period. The factors responsible for the increased cancer risks in forestry workers remain unclear and require further study.
 ...
PMID:Soft-tissue sarcoma, non-Hodgkin's lymphoma and other cancers in New Zealand forestry workers. 291 Aug 31

This paper presents a review and further analysis of a series of New Zealand case-control studies which have found elevated risks for soft tissue sarcoma (STS), non-Hodgkin's lymphoma (NHL), and acute myeloid leukemia (AML) in abattoir workers. The first published study involved 82 cases of STS (ICD 171) and found a relative risk of 2.8 (90% confidence interval 1.3-6.3). Interviews with an additional 51 cases reported here revealed a relative risk of 1.6 (90% confidence interval 0.9-3.0). Two further studies involved interviews with 100 cases of the category of NHL involving lymphosarcoma and reticulosarcoma (ICD 200) and 83 cases of other NHL (ICD 202). Relative risk estimates were 1.8 (90% confidence interval 1.1-2.9) and 1.7 (90% confidence interval 1.0-2.8), respectively. A study of 150 cases of AML (ICD 205.0) found a relative risk of 2.5 for abattoir workers (90% confidence interval 1.3-4.7). Finally, a United States cohort study found a standardized mortality ratio of 2.4 (90% confidence interval 0.8-5.4) for Hodgkin's disease (ICD 201) and 2.2 (90% confidence interval 0.8-4.5) for cancer of other lymphatic tissue (ICD 202, 203, 208) among abattoir workers. Abattoir workers are potentially exposed to oncogenic viruses, including bovine leukemia virus. Some workers may also be exposed to the animal carcinogen 2,4,6-trichlorophenol when treating pelts.
 ...
PMID:Increased risks of soft tissue sarcoma, malignant lymphoma, and acute myeloid leukemia in abattoir workers. 316 2

A significant number of patients with non-Hodgkin's lymphoma have peripheral blood involvement during the course of their disease. Because the expression of receptor for the lectin peanut agglutinin PNA by normal lymphocytes is associated with noncirculating (stationary phase) cells, we studied the relationship between PNA binding by lymphoma cells and the presence of clonal B cells in the blood of 38 patients with B-cell lymphoma. The binding of PNA by cells in tissues was determined by the immunoperoxidase method and by two-color flow cytometry. Circulating lymphoma cells (clonal B cells) were identified by a sensitive flow-cytometric technique (kappa-lambda analysis) and were also studied for PNA binding in some cases. In all, 16 of 38 (42%) of lymphomas were PNA+, including a spectrum of histologic types. Circulating lymphoma cells were demonstrated in 17 of 22 PNA-lymphomas, whereas only 3 of 16 of PNA+ lymphomas had such circulating cells. Thus, there is a significant association between PNA binding and peripheral blood involvement by lymphoma (P less than .005 by chi-square analysis). In 12 cases, the circulating and tissue lymphoma cells had similar expression of PNA receptor (2 PNA+ and 10 PNA- cases), indicating that modulation of the PNA binding sites did not occur. In three patients who presented with lymphosarcoma cell leukemia, the circulating malignant cells were PNA-. These findings suggest that for both normal and malignant lymphocytes the absence of binding sites for PNA is associated with the capacity of these cells to circulate freely.
 ...
PMID:Circulating malignant cells in non-Hodgkin's lymphoma: correlation with binding by peanut agglutinin. 340 96


1 2 Next >>